U.S. Diabetes Drugs Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Others), By Diabetes Type (Type 1 and Type 2), By Route of Administration (Oral, Subcutaneous, and Intravenous), By Distribution Channel (Online Pharmacies, Hospital Pharmacies, and Retail Pharmacies), and Country Forecast, 2023-2030

Last Updated: December 01, 2025 | Format: PDF | Report ID: FBI109115

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2019-2030
Base Year	2022
Estimated Year	2023
Forecast Period	2023-2030
Historical Period	2019-2021
Unit	Value (USD Billion)
Growth Rate	CAGR of 7.6% from 2023 to 2030
Segmentation	By Drug Class Insulin DPP-4 Inhibitors GLP-1 Receptor Agonists SGLT2 Inhibitors Others
	By Diabetes Type Type 1 Type 2
	By Route of Administration Oral Subcutaneous Intravenous
	By Distribution Channel Online pharmacies Hospital Pharmacies Retail Pharmacies